Jul32019UncategorizedCategory: UncategorizedBy importateur3 July 2019 Author: importateur Post navigationPreviousPrevious post:Interleukin-17 patent granted in EuropeNextNext post:Alizé Pharma 3Related PostsSix new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024Seven new projects supported by our Foundation8 January 2024Newsletter December 202318 December 2023Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023